GlassScriptPhysician profile
Christopher D Riemann
NPI 1962491571
$462,929.59
in general payments reported to CMS, 2019-2025
39 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $80K · 2021: $59K · 2022: $31K · 2023: $47K · 2024: $52K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $81K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Travel and Lodging: $14K · Honoraria: $11K · Food and Beverage: $8,547 · Royalty Or License: $7,733 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,444 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $81,089.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,200.00 |
| Travel and Lodging | $13,523.25 |
| Honoraria | $11,225.00 |
| Food and Beverage | $8,546.93 |
| Royalty Or License | $7,732.78 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,443.75 |
| Education | $141.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haag-Streit USA, INC. | $149,104.94 | 2019-2025 | |
| Medone Surgical INC | $99,828.94 | 2019-2025 | |
| Astellas Pharma US INC | $52,279.20 | 2023-2025 | Izervay |
| Dutch Ophthalmic Research Center (International) B.V. | $36,548.29 | 2021-2024 | Tissueblue, Eva, Combined Machine |
| Alcon Vision LLC | $23,208.78 | 2019-2024 | Ngenuity, Centurion, Clareon |
| W. L. Gore & Associates, INC. | $19,606.67 | 2019-2025 | Product In Development |
| Alcon Research LLC | $16,018.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $12,838.27 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $10,044.49 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Genentech, INC. | $8,218.79 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $6,076.81 | 2022-2025 | Xipere, Xiidra, Miebo |
| Alimera Sciences, INC. | $6,069.46 | 2019-2024 | Iluvien, Yutiq |
| Dutch Ophthalmic, USA | $4,202.05 | 2020-2025 | Tissueblue, Eva, Combined Machine |
| Carl Zeiss Meditec, INC. | $4,084.71 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $3,414.09 | 2021-2025 | Clarus, Cirrus 6000 With Angioplex, Retina Workplace |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,564.18 | 2020-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $2,293.56 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,870.97 | 2019-2021 | |
| Genentech USA, INC. | $991.95 | 2019-2025 | Vabysmo, Susvimo |
| Abbvie INC. | $821.33 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $764.81 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $624.32 | 2019-2023 | |
| Regeneron Pharmaceuticals, INC. | $255.59 | 2021-2025 | Eylea Hd, Eylea |
| Spark Therapeutics, INC. | $179.83 | 2019-2024 | Luxturna |
| Samsara Vision | $174.76 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Leica Microsystems INC. | $155.50 | 2025 | |
| Astellas US LLC | $135.72 | 2024 | Izervay |
| Biogen, INC. | $123.22 | 2022-2024 | Byooviz |
| Mallinckrodt Hospital Products INC. | $120.48 | 2024 | Acthar |
| Sandoz INC. | $97.76 | 2024 | Cimerli |
| Lombart Brothers, INC. | $56.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Astellas Pharma Global Development | $33.12 | 2024 | Izervay |
| Janssen Global Services, LLC | $28.72 | 2022 | |
| Amgen INC. | $21.88 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $17.06 | 2020 | |
| Lumibird Medical INC. | $11.21 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$93,038.24 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$123,011.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Riemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.